AVITA Medical, Inc. (NASDAQ:RCEL ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Jessica Ekeberg - Director, Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Chris Kallos - MST Access Operator Good day, and thank you for standing by. Welcome to AVITA Medical First Quarter 2025 Earnings Conference Call.
The mean of analysts' price targets for Avita Medical (RCEL) points to a 52.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
After Sales Rebound In January, AVITA Is Set Up For A Monster Year
AVITA Medical, Inc. (NASDAQ:RCEL ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Jessica Ekeberg - Director of Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Matthew Park - Cantor Fitzgerald Ryan Zimmerman - BTIG Brooks O'Neil - Lake Street Capital Markets Joshua Jennings - TD Cowen Operator Good day, and thank you for standing by. Welcome to the AVITA Medical Fourth Quarter 2024 Earnings Conference Call.
AVITA Medical's stock plummeted 36.4% after a significant Q4 sales miss, highlighting a pattern of guidance misses. Management's breakeven target shifted to Q4 2025. It also gave 2025 sales guidance of $100-$106 million. The Company will be forced to repay its $40 million OrbiMed loan if its sales follow my projections and company guidance.
AVITA Medical: A Dip Buy As 2025 Looks Bullish With Cohealyx And RECELL GO Mini
On Tuesday, Avita Medical, Inc. RCEL revised its revenue guidance for the fourth quarter and full year of 2024.
Lake Street analyst Brooks O'Neil lowered the firm's price target on Avita Medical to $14 from $20 and keeps a Buy rating on the shares after the company announced preliminary Q4 commercial revenue that was below the firm's estimate and consensus and management lowered the expected FY24 revenue outlook. The company also provided initial FY25 revenue guidance that was below the firm's previous revenue estimate, which Lake Street calls "disappointing." However, with shares off nearly 22% in the after hours, the firm is maintaining a Buy rating as it continues to think this is a significant year for Avita, the analyst added.
AVITA Medical's Australia-listed shares sank nearly 19% on Wednesday, set for their worst day in 15 months, after the regenerative medicine firm cut its forecast for the fourth time in five quarters and pushed out its profitability target.
AVITA Medical's Q3 report showed strong sequential sales growth and a lower burn rate. My confidence in it reaching breakeven by Q3 2025 has increased. The transition to RECELL GO has been highly successful, with 75% of the US sales base switching from the manual version. This is driving increased utilization. The total addressable market for AVITA's new ecosystem of products has expanded significantly, with the burning market TAM increasing from $450 million to $1.5 billion.
AVITA Medical, Inc. (NASDAQ:RCEL ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Jessica Ekeberg - Director, Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Ross Osborne - Cantor Fitzgerald Eric Anderson - TD Cowen John Hester - Bell Potter Chris Kallos - MST Access Operator Good day and thank you for standing by. Welcome to the AVITA Medical, Inc. Third Quarter 2024 Earnings Conference Call.
AVITA Medical's RECELL GO offers superior wound healing with less donor skin required, reducing scarring and infection risk. It has no direct competition. RECELL GO streamlines the skin grafting process, saving time and money. New products like PermeaDerm and Cohealyx offer additional growth opportunities. Despite the Q1 sales hiccup & high operating losses, AVITA's underlying technology still has promise. The stock should rally if the Q3 sales target is met & operating margins improve.